{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6"},{"groupId":"OG001","value":"30.6"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"To qualify as an objective response, CR and PR require confirmation at least 4 weeks after initial observation of complete response (CR) or partial response (PR). CR + PR = ORR","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"The analysis is limited to only participants with mCRPC who experienced a complete or partial response to study treatment. None of the participants in the control arm experienced a complete or partial response to study treatment. Participants in Part 2 did not have mCRPC, so were not eligible for response using PCWG3 criteria.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months,","title":"Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}